Friday, October 27, 2017 9:16:27 PM
r-
You do not understand or do not want to understand ... A given chart (e.g. for 3 months, daily, etc.) will be resulted in the same prediction by everybody (assuming all of them know TA), independently from the person.
TA has rules ... x form on a chart predict y "behavior" ... based on x form everybody "have to" conclude y, the form "could not" be interpreted differently, predict different y1, y2, ... "behavior". (e.g. Everybody when see 3 + 3, will say that the result will be 6.) ... Of course, TA isn't so explicit the x form on the chart does not guarantee the behavior but based on history (analysis of millions of charts) the outcome of y is the typical ... but typical does not mean in every cases.
F- did not make any conclusion (in a classical meaning) ... he analyzed the chart (acc. to TA rules, based on forms, etc.) and summarized the result of it.
So, meanwhile you would like to paint it as a challenge of F- it is the deny of TA ... which is fine, you could ... but ask F- why the TA is wrong ... well ...
Best,
G
You do not understand or do not want to understand ... A given chart (e.g. for 3 months, daily, etc.) will be resulted in the same prediction by everybody (assuming all of them know TA), independently from the person.
TA has rules ... x form on a chart predict y "behavior" ... based on x form everybody "have to" conclude y, the form "could not" be interpreted differently, predict different y1, y2, ... "behavior". (e.g. Everybody when see 3 + 3, will say that the result will be 6.) ... Of course, TA isn't so explicit the x form on the chart does not guarantee the behavior but based on history (analysis of millions of charts) the outcome of y is the typical ... but typical does not mean in every cases.
F- did not make any conclusion (in a classical meaning) ... he analyzed the chart (acc. to TA rules, based on forms, etc.) and summarized the result of it.
So, meanwhile you would like to paint it as a challenge of F- it is the deny of TA ... which is fine, you could ... but ask F- why the TA is wrong ... well ...
Best,
G
#NEWMIAMI
Disclosure: I am long with this stock. I wrote this post myself, and it expresses my own opinions (IMHO). I am not receiving compensation for it.
Do Your Job
Recent AMRN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
